Autres langues Takeda Pharmaceutical Company Limited Sao Paulo

Actions

TAKP34

BRTAKPBDR006

Temps Différé Sao Paulo Autres places de cotation 20:06:04 21/06/2024			Varia. 5j.	Varia. 1 janv.
68,53 ^BRL	-5,23%		-5,23%	-0,91%

11:02	Hutchmed China note que Takeda a obtenu l'approbation de l'UE pour Fruzaqla	AN
10:45	Le traitement de l'infection des greffes d'organes de Takeda approuvé par les autorités japonaises	MT

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Hutchmed China notes Takeda obtains EU approval for Fruzaqla	11:02
Takeda's Organ Transplant Infection Treatment Approved by Japan Regulators	10:45
Hutchmed (China), Takeda Secure EU Approval for Colorectal Cancer Treatment	09:59
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies	09:01
Japanese Shares End Higher as BoJ Indicates Readiness for Policy Shifts	08:29
Takeda Receives European Commission Approval for Colorectal Cancer Treatment	05:08
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia	23/06
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia	23/06
Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla	21/06
Takeda Pharmaceutical Gets European Commission Approval for Cancer Treatment	21/06
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer	21/06
Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer	21/06
Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older	21/06
Japanese Stocks End Little Changed After Three-Day Winning Streak on Inflation and Yen Woes	21/06
Borsa di Italia: Le streghe terrorizzano l'AI	21/06
Bolsa de Madrid: Las brujas aterrorizan a la IA	21/06
Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India	21/06
Sun Pharma Signs Deal with Japan's Takeda to Commercialize Vonoprazan in India	21/06
Sun Pharma Signs Non-Exclusive Patent Licensing Agreement with Takeda for Introducing Novel Gastrointestinal Drug, Voltapraz in India	21/06
Takeda presenta datos de largo plazo del ensayo clínico de fase 3 ADVANCE-CIDP 3 de HYQVIA® en pacientes con polineuropatía desmielinizante inflamatoria crónica (PDIC) en la Reunión Anual de la PNS	19/06

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Takeda Pharmaceutical Company Limited Sao Paulo

Actions

TAKP34

BRTAKPBDR006

Autres langues

Filtres